TerlipressinThird Party Manufacturing in India

Terlipressin works as a synthetic vasopressin analogue and prodrug that exerts powerful vasoconstrictor effects through activation of V1a receptors on vascular smooth muscle cells. When administered intravenously, terlipressin is cleaved in vivo by endopeptidases to yield lysine-vasopressin, the active metabolite. This metabolite binds with high affinity to V1a receptors on splanchnic arterioles, activating the Gq/11-phospholipase C pathway. This triggers an IP3-mediated calcium release from intracellular stores, producing strong and sustained splanchnic vasoconstriction. By constricting the splanchnic circulation, terlipressin reduces portal venous inflow and lowers portal pressure, which is critical in managing esophageal variceal bleeding. The splanchnic vasoconstriction also redirects blood flow to the systemic circulation, improving effective arterial blood volume and renal perfusion. This hemodynamic improvement in renal blood flow and glomerular filtration rate is the basis for its use in hepatorenal syndrome type 1. Unlike native vasopressin, terlipressin has a longer biological half-life allowing bolus dosing every 4-6 hours rather than continuous infusion.

Therapeutic Uses

Terlipressin is a hospital-use vasoactive agent prescribed for:

• Hepatorenal Syndrome Type 1 (HRS-1): FDA-approved for reversing acute kidney injury in cirrhotic patients by improving renal blood flow through splanchnic vasoconstriction and albumin co-administration.
• Esophageal Variceal Bleeding: Standard of care in Europe and Asia for controlling acute variceal hemorrhage in portal hypertension patients. Reduces mortality compared to other vasoactive agents.
• Refractory Hypotension in Cirrhosis: Used off-label for managing hypotension in patients with decompensated cirrhosis who do not respond to conventional vasopressors.

Why Manufacturers Choose Terlipressin

Terlipressin is a critical care medicine included in the WHO Essential Medicines List and is increasingly manufactured by Indian pharma companies. The market has grown with FDA approval (Terlivaz) in 2022, expanding demand from US hospitals. The lyophilized injection formulation requires specialized aseptic manufacturing capability, making it a value-added product for WHO-GMP certified injectable facilities. Indian manufacturers with expertise in peptide-based injectables and lyophilized products are well-positioned to supply this molecule to both domestic and export markets. This makes Terlipressin a strategic molecule for third party manufacturing in India, with growing demand from hospital tenders and institutional buyers worldwide.